Article

[Retrospective analysis of amrubicin hydrochloride monotherapy in patients with previously treated small-cell lung cancer].

Department of Respiratory Disease, Hiroshima Red Cross Hospital and Atomic Bomb Survivors Hospital.
Gan to kagaku ryoho. Cancer & chemotherapy 06/2010; 37(6):1045-9. pp.1045-9
Source: PubMed

ABSTRACT We retrospectively investigated amrubicin hydrochloride(AMR)monotherapy as second or thirdline chemotherapy for small-cell lung cancer(SCLC)and assessed its efficacy and safety. AMR was intravenously administered at 25-45mg/m2 for 3 consecutive days every 3-4 weeks. Fifty-three patients were enrolled. Response rates and median survival times were as follows: total cases, 32% and 7. 4 months; sensitive relapse cases, 64% and 16. 4 months; refractory relapse cases, 27% and 5. 9 months. Neutropenia was major toxicity(Grade 3 or 4 was observed in 72% of the subjects), whereas nonhematologic toxicities were mild. Treatment with AMR appeared effective in SCLC patients previously treated with chemotherapy. On the other hand, it must be used carefully because of its relatively severe hematologic toxicities.

0 0
 · 
0 Bookmarks
 · 
25 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

3 consecutive days
 
3-4 weeks
 
amrubicin hydrochloride(AMR)monotherapy
 
median survival times
 
Neutropenia
 
nonhematologic toxicities
 
refractory relapse cases
 
Response rates
 
sensitive relapse cases
 
severe hematologic toxicities
 
small-cell lung cancer(SCLC)and
 
total cases